Home Cart Sign in  
Chemical Structure| 130-00-7 Chemical Structure| 130-00-7

Structure of 130-00-7

Chemical Structure| 130-00-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 130-00-7 ]

CAS No. :130-00-7
Formula : C11H7NO
M.W : 169.18
SMILES Code : O=C1NC2=C3C1=CC=CC3=CC=C2
MDL No. :MFCD00009748
InChI Key :GPYLCFQEKPUWLD-UHFFFAOYSA-N
Pubchem ID :67222

Safety of [ 130-00-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 130-00-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 12
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 53.26
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

32.86 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.64
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.09
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.12
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.4
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.35
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.32

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.89
Solubility 0.219 mg/ml ; 0.00129 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.41
Solubility 0.658 mg/ml ; 0.00389 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.43
Solubility 0.00621 mg/ml ; 0.0000367 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.85 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.47

Application In Synthesis of [ 130-00-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 130-00-7 ]

[ 130-00-7 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 130-00-7 ]
  • [ 78078-92-9 ]
YieldReaction ConditionsOperation in experiment
26% With chlorosulfonic acid; FIGURE 72 shows the synthesis of TNF-alpha binding bifunctional molecule 4e-GN3.
With chlorosulfonic acid; In chloroform; at 0 - 50℃; for 5.5h; To a solution of benzo [cd]indol-2(1H)-one 2 (10g, 60mmol) in chloroform (150mL) was added batches of chlorosulfonic acid (22mL, 6.0 equiv.) at 0C for 30min. The reaction mixture was heated at 50C for 5h. The mixture was then poured into ice water and extracted with CHCl3 (100mL×3). The organic layer was washed with brine and dried over Na2SO4. The solid was filtered off, and the filtrate was concentrated under reduced pressure to afford 2-oxo-1,2-dihydrobenzo [cd]indole-6-sulfonyl chloride (10g, yield 50%). The resulting crude product was resolved in dichloromethane (100mL), then the solution was added into pyrrolidine (3.4mL, 1.2 equiv.) and N-ethyldi isopropylamine (DIPEA, 18mL, 3.0 equiv.). The reaction mixture was stirred at room temperature for 5h. After completion of the reaction as monitored by TLC, dilute HCl was added, the aqueous layer was extracted with DCM (80mL×3), and the organic layer was washed with water and brine, dried with Na2SO4, and evaporated to give 6-(pyrrolidin-1-ylsulfonyl) benzo [cd]indol-2(1H)-one 3 (9g, yield 80%). The product 3 (150mg, 0.5mmol) and sodium hydride (NaH, 36mg, 1.5mmol) were dissolved in DMF (15mL). Bromoethane (65.4mg, 0.6mmol) was added dropwise into the solution and the reaction mixture was stirred at room temperature. After completion of the reaction as monitored by TLC, the reaction mixture was extracted with ethyl acetate (10mL×2). The organic layer was washed with brine and dried over Na2SO4. The solid was filtered off, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (3/1, v/v) to yield compound 1. Under the same conditions, compounds 4-9 were obtained (for detail, see Supporting information 1 and 2). 4.2.1 1-Ethyl-6-(pyrrolidin-1-ylsulfonyl)benzo[cd]indol-2(1H)-one (1) Yellow-green solid, yield 77%, m. p. 168.1-168.9C; 1H NMR (600MHz, CDCl3) delta (ppm): 8.79 (d, J=8.4Hz, 1H), 8.16 (d, J=7.2Hz, 1H), 8.11 (d, J=7.2Hz, 1H), 7.83 (t, J=7.8Hz, 1H), 6.96 (d, J=7.8Hz, 1H), 3.99 (q, J=7.2Hz, 2H), 3.31 (t, J=6.6Hz, 4H), 1.79-1.77 (m, 4H), 1.39 (t, J=7.2Hz, 3H); 13C NMR (150MHz, CDCl3) delta (ppm): 167.6 (C=O), 143.6, 132.9 (CH), 130.4 (CH), 130.3 (CH), 127.0, 126.5, 125.8 (2C), 125.2 (CH), 103.0 (CH), 47.5 (2CH2), 35.1(CH2), 25.3 (2CH2), 13.9 (CH3); HRMS (ESI): Calcd for C17H18N2O3SNa ([M+Na]+): 353.0936, Found: 353.0932. Anal. Calcd for C17H18N2O3S: C, 61.80; H, 5.49; N, 8.48. Found: C, 61.78; H, 5.52; N, 8.49.
 

Historical Records

Technical Information

Categories